Combined inhibition of the IL-6/STAT3 pathway (by Tocilizumab) and HMGB1 (by knockdown) resulted in suppression of enzalutamide-induced NE differentiation in PCa, indicating that dual targeting of IL-6 and HMGB1 may serve as a promising treatment option for enzalutamide-resistant PCa [173]. Here, IL6 is linked to posterior cortical atrophy.